BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Brunet M, van Gelder T, Åsberg A, Haufroid V, Hesselink DA, Langman L, Lemaitre F, Marquet P, Seger C, Shipkova M, Vinks A, Wallemacq P, Wieland E, Woillard JB, Barten MJ, Budde K, Colom H, Dieterlen M, Elens L, Johnson-davis KL, Kunicki PK, Macphee I, Masuda S, Mathew BS, Millán O, Mizuno T, Moes DAR, Monchaud C, Noceti O, Pawinski T, Picard N, van Schaik R, Sommerer C, Vethe NT, de Winter B, Christians U, Bergan S. Therapeutic Drug Monitoring of Tacrolimus-Personalized Therapy: Second Consensus Report. Therapeutic Drug Monitoring 2019;41:261-307. [DOI: 10.1097/ftd.0000000000000640] [Cited by in Crossref: 219] [Cited by in F6Publishing: 227] [Article Influence: 73.0] [Reference Citation Analysis]
Number Citing Articles
1 Deprez S, Heughebaert L, Boffel L, Stove CP. Application OF NON-CONTACT hematocrit prediction technologies to overcome hematocrit effects on immunosuppressant quantification from dried blood spots. Talanta 2022. [DOI: 10.1016/j.talanta.2022.124111] [Reference Citation Analysis]
2 Cholbi Vives E, Espí Reig J, Cruz Sánchez A, Moreno Maestre E, Ventura Galiano A, Ramos Escorihuela D, Ramos Cebrián M, González-calero Borrás P, Beneyto Castelló I, Hernández Jaras J. Comparative Study of 2 Extended-Release Tacrolimus Formulations in Kidney Transplantation. Transplantation Proceedings 2022. [DOI: 10.1016/j.transproceed.2022.10.001] [Reference Citation Analysis]
3 Zhu H, Wang M, Xiong X, Du Y, Li D, Wang Z, Ge W, Zhu Y. Plasma metabolomic profiling reveals factors associated with dose-adjusted trough concentration of tacrolimus in liver transplant recipients. Front Pharmacol 2022;13. [DOI: 10.3389/fphar.2022.1045843] [Reference Citation Analysis]
4 Oellerich M, Budde K, Osmanodja B, Bornemann-kolatzki K, Beck J, Schütz E, Walson PD. Donor-derived cell-free DNA as a diagnostic tool in transplantation. Front Genet 2022;13:1031894. [DOI: 10.3389/fgene.2022.1031894] [Reference Citation Analysis]
5 Leino AD, Takyi-Williams J, Wen B, Sun D, Pai MP. Application of a new volumetric microsampling device for quantitative bioanalysis of immunosuppression. Bioanalysis 2022. [PMID: 36208082 DOI: 10.4155/bio-2022-0155] [Reference Citation Analysis]
6 Zheng X, Ye J, Chen W, Wang X, Li J, Su F, Ding C, Huang Y. Ultrasensitive Sandwich-Type SERS-Biosensor-Based Dual Plasmonic Superstructure for Detection of Tacrolimus in Patients. ACS Sens 2022. [PMID: 36206537 DOI: 10.1021/acssensors.2c01603] [Reference Citation Analysis]
7 Belaiche S, Lassailly G, Amrani ME, Canva V, Boleslawski E, Lebuffe G, Decaudin B, Dharancy S. Immunosuppression in liver transplanted patients with short bowel syndrome. Journal of Liver Transplantation 2022;8:100115. [DOI: 10.1016/j.liver.2022.100115] [Reference Citation Analysis]
8 Kim HJ, Lee J, Lee JG, Joo DJ, Kim MS. Clinical association between tacrolimus intra-patient variability and liver transplantation outcomes in patients with and without hepatocellular carcinoma. Sci Rep 2022;12:16169. [PMID: 36171260 DOI: 10.1038/s41598-022-20636-3] [Reference Citation Analysis]
9 Cui Y, Zhu M, Pan Y, Jiao Z. Pharmacokinetic Evaluation of Tacrolimus in Chinese Adult Patients Receiving Voriconazole During the Early Stage Post-Lung Transplantation.. [DOI: 10.21203/rs.3.rs-2071384/v1] [Reference Citation Analysis]
10 In 't Veld AE, Jansen MAA, Huisman BW, Schoonakker M, de Kam ML, Moes DJAR, van Poelgeest MIE, Burggraaf J, Moerland M. Monitoring of Ex Vivo Cyclosporin a Activity in Healthy Volunteers Using T Cell Function Assays in Relation to Whole Blood and Cellular Pharmacokinetics. Pharmaceutics 2022;14:1958. [PMID: 36145707 DOI: 10.3390/pharmaceutics14091958] [Reference Citation Analysis]
11 Obayemi J, Keating B, Callans L, Lentine KL, Schnitzler MA, Caliskan Y, Xiao H, Dharnidharka VR, Mannon RB, Axelrod DA. Impact of CYP3A5 Status on the Clinical and Financial Outcomes Among African American Kidney Transplant Recipients. Transplant Direct 2022;8:e1379. [PMID: 36204191 DOI: 10.1097/TXD.0000000000001379] [Reference Citation Analysis]
12 Qu J, Bian R, Liu B, Chen J, Zhai J, Teng F, Guo W, Wei H. The pharmacokinetic study of tacrolimus and Wuzhi capsule in Chinese liver transplant patients. Front Pharmacol 2022;13:956166. [DOI: 10.3389/fphar.2022.956166] [Reference Citation Analysis]
13 Udomkarnjananun S, Francke MI, Dieterich M, van De Velde D, Litjens NHR, Boer K, De Winter BCM, Baan CC, Hesselink DA. P-glycoprotein, FK-binding Protein-12, and the Intracellular Tacrolimus Concentration in T-lymphocytes and Monocytes of Kidney Transplant Recipients. Transplantation 2022. [PMID: 36070572 DOI: 10.1097/TP.0000000000004287] [Reference Citation Analysis]
14 Zahr N, Duce H, Duffy J, Webster C, Rentsch KM. Interlaboratory comparison study of immunosuppressant analysis using a fully automated LC-MS/MS system. Clin Chem Lab Med 2022. [PMID: 36044751 DOI: 10.1515/cclm-2021-1340] [Reference Citation Analysis]
15 Song X, Liu F, Gao H, Yan M, Zhang F, Zhao J, Qin Y, Li Y, Zhang Y. Compare the performance of multiple machine learning models in predicting tacrolimus concentration for infant patients with living donor liver transplantation. Pediatr Transplant 2022;:e14379. [PMID: 36039686 DOI: 10.1111/petr.14379] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
16 Francke MI, van Domburg B, Bouarfa S, van de Velde D, Hellemons ME, Manintveld OC, Last-Koopmans S, Mulder MB, Hesselink DA, de Winter BCM. The Clinical Validation Of A Dried Blood Spot Method For Simultaneous Measurement Of Cyclosporine A, Tacrolimus, Creatinine, And Hematocrit. Clin Chim Acta 2022:S0009-8981(22)01265-7. [PMID: 36007582 DOI: 10.1016/j.cca.2022.08.014] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
17 Brunet M, Pastor-anglada M. Insights into the Pharmacogenetics of Tacrolimus Pharmacokinetics and Pharmacodynamics. Pharmaceutics 2022;14:1755. [DOI: 10.3390/pharmaceutics14091755] [Reference Citation Analysis]
18 Xu Q, Dong Y, Niu W, Zheng X, Li R, Zhang M, Wang Z, Qiu X. TLR10 genotypes affect long-term graft function in tacrolimus-treated solid organ transplant recipients. Int Immunopharmacol 2022;111:109160. [PMID: 35994854 DOI: 10.1016/j.intimp.2022.109160] [Reference Citation Analysis]
19 Hirai T, Ino K, Ikejiri M, Tawara I, Iwamoto T. Dual Inhibition of CYP3A4 by Voriconazole and Clarithromycin Influences Tacrolimus Pharmacokinetics: Case Series Study. Eur J Drug Metab Pharmacokinet 2022. [PMID: 35978155 DOI: 10.1007/s13318-022-00790-9] [Reference Citation Analysis]
20 Labriffe M, Woillard J, Debord J, Marquet P. Machine learning algorithms to estimate everolimus exposure trained on simulated and patient pharmacokinetic profiles. CPT Pharmacom & Syst Pharma 2022;11:1018-1028. [DOI: 10.1002/psp4.12810] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
21 Coste G, Robin F, Chemouny J, Tron C, Le Priol J, Bouvet R, Le Vée M, Houssel-debry P, Rayar M, Verdier M, Roussel M, Galibert M, Bardou-jacquet E, Fardel O, Vigneau C, Boudjema K, Laviolle B, Lemaitre F. Drug transporters are implicated in the diffusion of tacrolimus into the T lymphocyte in kidney and liver transplant recipients: Genetic, mRNA, protein expression, and functionality. Drug Metabolism and Pharmacokinetics 2022. [DOI: 10.1016/j.dmpk.2022.100473] [Reference Citation Analysis]
22 Liu XL, Guan YP, Wang Y, Huang K, Jiang FL, Wang J, Yu QH, Qiu KF, Huang M, Wu JY, Zhou DH, Zhong GP, Yu XX. Population Pharmacokinetics and Initial Dosage Optimization of Tacrolimus in Pediatric Hematopoietic Stem Cell Transplant Patients. Front Pharmacol 2022;13:891648. [PMID: 35873585 DOI: 10.3389/fphar.2022.891648] [Reference Citation Analysis]
23 El-souri M, Dayco JS, Afonso L. Inspirations from a Complicated Pediatric Heart Transplantation. JACC: Case Reports 2022;4:915-918. [DOI: 10.1016/j.jaccas.2022.05.026] [Reference Citation Analysis]
24 Storas AM, Asberg A, Halvorsen P, Riegler MA, Strumke I. Predicting Tacrolimus Exposure in Kidney Transplanted Patients Using Machine Learning. 2022 IEEE 35th International Symposium on Computer-Based Medical Systems (CBMS) 2022. [DOI: 10.1109/cbms55023.2022.00014] [Reference Citation Analysis]
25 Lo Re F, Angelini J, Sponga S, Nalli C, Zucchetto A, Biasizzo J, Livi U, Baraldo M. Therapeutic Drug Monitoring of Mycophenolic Acid as a Precision Medicine Tool for Heart Transplant Patients: Results of an Observational Pharmacokinetic Pilot Study. Pharmaceutics 2022;14:1304. [PMID: 35745876 DOI: 10.3390/pharmaceutics14061304] [Reference Citation Analysis]
26 Zhang Q, Tian X, Chen G, Yu Z, Zhang X, Lu J, Zhang J, Wang P, Hao X, Huang Y, Wang Z, Gao F, Yang J. A Prediction Model for Tacrolimus Daily Dose in Kidney Transplant Recipients With Machine Learning and Deep Learning Techniques. Front Med (Lausanne) 2022;9:813117. [PMID: 35712101 DOI: 10.3389/fmed.2022.813117] [Reference Citation Analysis]
27 Storås AM, Strümke I, Riegler MA, Halvorsen P. Explainability methods for machine learning systems for multimodal medical datasets. Proceedings of the 13th ACM Multimedia Systems Conference 2022. [DOI: 10.1145/3524273.3533925] [Reference Citation Analysis]
28 Ky TQ, Silas NP, Taylor RM, Barakat AO, Harb R, Laviste NC, Park JM. Evaluation of a Standardized Tacrolimus Therapeutic Drug Monitoring Protocol in Stable Kidney Transplant Recipients. Prog Transplant 2022;:15269248221107043. [PMID: 35695240 DOI: 10.1177/15269248221107043] [Reference Citation Analysis]
29 De Gregori S, De Silvestri A, Cattadori B, Rapagnani A, Albertini R, Novello E, Concardi M, Arbustini E, Pellegrini C. Therapeutic Drug Monitoring of Tacrolimus-Personalized Therapy in Heart Transplantation: New Strategies and Preliminary Results in Endomyocardial Biopsies. Pharmaceutics 2022;14:1247. [PMID: 35745819 DOI: 10.3390/pharmaceutics14061247] [Reference Citation Analysis]
30 Marschner MN, Chandran MM, Colyer LG. Artificially Elevated Tacrolimus Concentrations Obtained From a Venous Catheter Previously Used for Tacrolimus Administration in a Pediatric Patient. J Pharm Pract 2022;:8971900221107841. [PMID: 35689341 DOI: 10.1177/08971900221107841] [Reference Citation Analysis]
31 Zhang W, Matsukane R, Egashira N, Tsuchiya Y, Fu R, Yamamoto S, Hirota T, Ieiri I. Neuroprotective effects of ibudilast against tacrolimus induced neurotoxicity. Toxicology and Applied Pharmacology 2022. [DOI: 10.1016/j.taap.2022.116112] [Reference Citation Analysis]
32 Du Y, Song W, Xiong XF, Ge WH, Huai-Jun Z. Population pharmacokinetics and dosage optimization of tacrolimus coadministration with Wuzhi capsule in adult liver transplant patients. Xenobiotica 2022;:1-33. [PMID: 35502774 DOI: 10.1080/00498254.2022.2073851] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
33 Warzyszyńska K, Zawistowski M, Karpeta E, Jałbrzykowska A, Kosieradzki M. Renal Cyp3a5-Expressing Genotype Decreases Tacrolimus-to-Dose Ratio in Small Cohort of Renal Transplant Recipients—Preliminary Report. Transplantation Proceedings 2022. [DOI: 10.1016/j.transproceed.2022.02.018] [Reference Citation Analysis]
34 Djabarouti S, Mora P, Lahouati M, Gigan M, d’Houdain N, Sourisseau B, Chambord J, Xuereb F. Intérêt des dosages pharmacologiques d’immunosuppresseurs et immunomodulateurs dans la prise en charge des maladies autoimmunes. La Revue de Médecine Interne 2022. [DOI: 10.1016/j.revmed.2022.03.343] [Reference Citation Analysis]
35 Susan Mathew B, Mathew SK, Winston Aruldhas B, Prabha R, Gangadharan N, George David V, Varughese S, Tharayil John G. Analytical and clinical validation of Dried blood spot and Volumetric Absorptive Microsampling for measurement of tacrolimus and creatinine after renal transplantation. Clin Biochem 2022:S0009-9120(22)00117-5. [PMID: 35490728 DOI: 10.1016/j.clinbiochem.2022.04.014] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
36 Franken LG, Francke MI, Andrews LM, van Schaik RHN, Li Y, de Wit LEA, Baan CC, Hesselink DA, de Winter BCM. A Population Pharmacokinetic Model of Whole-Blood and Intracellular Tacrolimus in Kidney Transplant Recipients. Eur J Drug Metab Pharmacokinet 2022. [PMID: 35442010 DOI: 10.1007/s13318-022-00767-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
37 Zhang SF, Tang BH, An-Hua W, Du Y, Guan ZW, Li Y. Effect of drug combination on tacrolimus target dose in renal transplant patients with different CYP3A5 genotypes. Xenobiotica 2022;:1-33. [PMID: 35395919 DOI: 10.1080/00498254.2022.2064252] [Reference Citation Analysis]
38 Liu M, Shaver CM, Birdwell KA, Heeney SA, Shaffer CM, Van Driest SL. Composite CYP3A phenotypes influence tacrolimus dose-adjusted concentration in lung transplant recipients. Pharmacogenet Genomics 2022. [PMID: 35389944 DOI: 10.1097/FPC.0000000000000472] [Reference Citation Analysis]
39 Cremers S, Lyashchenko A, Rai AJ, Hayden J, Dasgupta A, Tsapepas D, Mohan S. Challenged comparison of tacrolimus assays. Scandinavian Journal of Clinical and Laboratory Investigation. [DOI: 10.1080/00365513.2022.2056858] [Reference Citation Analysis]
40 Wu L, Ye Z, Zhang X, Zheng A, Zhang X, Chen L, Ouyang D, Zheng L, Liu X. Development and evaluation of a new test kit for determination of immunosuppressants in blood by UHPLC-MS/MS. Journal of Pharmaceutical and Biomedical Analysis 2022. [DOI: 10.1016/j.jpba.2022.114756] [Reference Citation Analysis]
41 Willigenburg HV, Domburg BV, Ambagtsheer G, Brandt RM, Hesselink DA, de Bruin RW, de Winter BC. Validation of a dried blood spot method to measure tacrolimus concentrations in small volumes of mouse blood. Bioanalysis 2022. [PMID: 35289217 DOI: 10.4155/bio-2021-0247] [Reference Citation Analysis]
42 Bodnar-broniarczyk M, Warzyszyńska K, Czerwińska K, Marszałek D, Dziewa N, Kosieradzki M, Pawiński T. Development and Validation of the New Liquid Chromatography-Tandem Mass Spectrometry Method for the Determination of Unbound Tacrolimus in the Plasma Ultrafiltrate of Transplant Recipients. Pharmaceutics 2022;14:632. [DOI: 10.3390/pharmaceutics14030632] [Reference Citation Analysis]
43 Faelens R, Luyckx N, Kuypers D, Bouillon T, Annaert P. Predicting model‐informed precision dosing: A test‐case in tacrolimus dose adaptation for kidney transplant recipients. CPT Pharmacom & Syst Pharma 2022;11:348-361. [DOI: 10.1002/psp4.12758] [Reference Citation Analysis]
44 Santulario Verdú L, García-romero E, Díez-lópez C. Clinical impact of variability in blood concentrations of calcineurin inhibitors in heart transplant: a double-edged sword. Revista Española de Cardiología (English Edition) 2022;75:112-114. [DOI: 10.1016/j.rec.2021.08.012] [Reference Citation Analysis]
45 Santulario Verdú L, García-romero E, Díez-lópez C. Impacto clínico de la variabilidad en la concentración sanguínea de inhibidores de calcineurina en trasplante cardiaco: una espada de doble filo. Revista Española de Cardiología 2022;75:112-4. [DOI: 10.1016/j.recesp.2021.08.019] [Reference Citation Analysis]
46 Tornatore KM, Meaney CJ, Attwood K, Brazeau DA, Wilding GE, Consiglio JD, Gundroo A, Chang SS, Gray V, Cooper LM, Venuto RC. Race and sex associations with tacrolimus pharmacokinetics in stable kidney transplant recipients. Pharmacotherapy 2022;42:94-105. [DOI: 10.1002/phar.2656] [Reference Citation Analysis]
47 Dong Y, Xu Q, Li R, Tao Y, Zhang Q, Li J, Ma Z, Shen C, Zhong M, Wang Z, Qiu X. CYP3A7, CYP3A4, and CYP3A5 genetic polymorphisms in recipients rather than donors influence tacrolimus concentrations in the early stages after liver transplantation. Gene 2022;809:146007. [PMID: 34688813 DOI: 10.1016/j.gene.2021.146007] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
48 Huang L, Wang J, Yang J, Zhang H, Hu Y, Miao J, Mao J, Fang L. Impact of Sampling Time Variability on Tacrolimus Dosage Regimen in Pediatric Primary Nephrotic Syndrome: Single-Center, Prospective, Observational Study. Front Pharmacol 2021;12:726667. [PMID: 35069185 DOI: 10.3389/fphar.2021.726667] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
49 Pan F, Cao S, Li XL, Jia YN, Wang RL, He Q, Zhu JQ. The Model for End-Stage Liver Disease Score and the Follow-Up Period Can Cause the Shift of Circulating Lymphocyte Subsets in Liver Transplant Recipients. Front Med (Lausanne) 2021;8:779443. [PMID: 35047528 DOI: 10.3389/fmed.2021.779443] [Reference Citation Analysis]
50 Schmulenson E, Zimmermann N, Mikus G, Joerger M, Jaehde U. Current status and future outlooks on therapeutic drug monitoring of fluorouracil. Expert Opin Drug Metab Toxicol 2022. [PMID: 35029518 DOI: 10.1080/17425255.2021.2029403] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
51 Macphee IAM. Immunosuppression for Renal Transplantation. Primer on Nephrology 2022. [DOI: 10.1007/978-3-030-76419-7_93] [Reference Citation Analysis]
52 Hussain Y, Khan H. Immunosuppressive Drugs. Encyclopedia of Infection and Immunity 2022. [DOI: 10.1016/b978-0-12-818731-9.00068-9] [Reference Citation Analysis]
53 Staatz CE, Isbel NM, Bergmann TK, Jespersen B, Buus NH. Editorial: Therapeutic Drug Monitoring in Solid Organ Transplantation. Front Pharmacol 2021;12:815117. [PMID: 34955866 DOI: 10.3389/fphar.2021.815117] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
54 Srinivas L, Gracious N, Nair RR. Pharmacogenetics Based Dose Prediction Model for Initial Tacrolimus Dosing in Renal Transplant Recipients. Front Pharmacol 2021;12:726784. [PMID: 34916931 DOI: 10.3389/fphar.2021.726784] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
55 Bunthof KLW, Al-Hassany L, Nakshbandi G, Hesselink DA, van Schaik RHN, Ten Dam MAGJ, Baas MC, Hilbrands LB, van Gelder T. A randomized crossover study comparing different tacrolimus formulations to reduce intrapatient variability in tacrolimus exposure in kidney transplant recipients. Clin Transl Sci 2021. [PMID: 34905302 DOI: 10.1111/cts.13206] [Reference Citation Analysis]
56 Boosman RJ, Burgers JA, Smit EF, Steeghs N, van der Wekken AJ, Beijnen JH, Huitema ADR, Ter Heine R. Optimized Dosing: The Next Step in Precision Medicine in Non-Small-Cell Lung Cancer. Drugs 2021. [PMID: 34894338 DOI: 10.1007/s40265-021-01654-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
57 Francke MI, Andrews LM, Lan Le H, van de Velde D, Dieterich M, Udomkarnjananun S, Clahsen-van Groningen MC, Baan CC, van Gelder T, de Winter BCM, Hesselink DA. Monitoring intracellular tacrolimus concentrations and its relationship with rejection in the early phase after renal transplantation. Clin Biochem 2021:S0009-9120(21)00319-2. [PMID: 34890583 DOI: 10.1016/j.clinbiochem.2021.12.002] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
58 Cheng F, Li Q, Wang J, Hu M, Zeng F, Wang Z, Zhang Y. Genetic Polymorphisms Affecting Tacrolimus Metabolism and the Relationship to Post-Transplant Outcomes in Kidney Transplant Recipients. Pharmgenomics Pers Med 2021;14:1463-74. [PMID: 34824543 DOI: 10.2147/PGPM.S337947] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
59 De Nicolò A, Pinon M, Palermiti A, Nonnato A, Manca A, Mula J, Catalano S, Tandoi F, Romagnoli R, D'Avolio A, Calvo PL. Monitoring Tacrolimus Concentrations in Whole Blood and Peripheral Blood Mononuclear Cells: Inter- and Intra-Patient Variability in a Cohort of Pediatric Patients. Front Pharmacol 2021;12:750433. [PMID: 34803692 DOI: 10.3389/fphar.2021.750433] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
60 Fu Q, Jing Y, Liu Mr G, Jiang Mr X, Liu H, Kong Y, Hou X, Cao L, Deng P, Xiao P, Xiao J, Peng H, Wei X. Machine learning-based method for tacrolimus dose predictions in Chinese kidney transplant perioperative patients. J Clin Pharm Ther 2021. [PMID: 34802160 DOI: 10.1111/jcpt.13579] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
61 Balevic SJ, Sagcal-Gironella ACP. Precision Medicine: Towards Individualized Dosing in Pediatric Rheumatology. Rheum Dis Clin North Am 2022;48:305-30. [PMID: 34798954 DOI: 10.1016/j.rdc.2021.09.010] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
62 Stefanović N, Veličković-Radovanović R, Danković K, Pavlović I, Catić-Đorđević A, Bašić J, Despotović M, Jevtović-Stoimenov T, Mitić B, Cvetković T. Effect of the Interrelation between CYP3A5 Genotype, Concentration/Dose Ratio and Intrapatient Variability of Tacrolimus on Kidney Graft Function: Monte Carlo Simulation Approach. Pharmaceutics 2021;13:1970. [PMID: 34834385 DOI: 10.3390/pharmaceutics13111970] [Reference Citation Analysis]
63 Chavant A, Fonrose X, Gautier-Veyret E, Hilleret MN, Roustit M, Stanke-Labesque F. Variability of Tacrolimus Trough Concentration in Liver Transplant Patients: Which Role of Inflammation? Pharmaceutics 2021;13:1960. [PMID: 34834375 DOI: 10.3390/pharmaceutics13111960] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
64 Jin B, Kim GY, Cheon SM. Tacrolimus-induced neurotoxicity from bipolar disorder to status epilepticus under the therapeutic serum level: a case report. BMC Neurol 2021;21:448. [PMID: 34781882 DOI: 10.1186/s12883-021-02479-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
65 Sallustio BC. Monitoring Intra-cellular Tacrolimus Concentrations in Solid Organ Transplantation: Use of Peripheral Blood Mononuclear Cells and Graft Biopsy Tissue. Front Pharmacol 2021;12:733285. [PMID: 34764868 DOI: 10.3389/fphar.2021.733285] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
66 Déri M, Szakál-Tóth Z, Fekete F, Mangó K, Incze E, Minus A, Merkely B, Sax B, Monostory K. CYP3A-status is associated with blood concentration and dose-requirement of tacrolimus in heart transplant recipients. Sci Rep 2021;11:21389. [PMID: 34725418 DOI: 10.1038/s41598-021-00942-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
67 Huang L, Assiri AA, Wen P, Zhang K, Fan J, Xing T, Liu Y, Zhang J, Wang Z, Su Z, Chen J, Xiao Y, Wang R, Na R, Yuan L, Liu D, Xia J, Zhong L, Liu W, Guo W, Overholser BR, Peng Z. The CYP3A5 genotypes of both liver transplant recipients and donors influence the time-dependent recovery of tacrolimus clearance during the early stage following transplantation. Clin Transl Med 2021;11:e542. [PMID: 34709766 DOI: 10.1002/ctm2.542] [Reference Citation Analysis]
68 Kou K, Sun X, Li M, Li T, Hu Y, Li S, Lv G. Beneficial effects of Wuzhi Capsule on tacrolimus blood concentrations in liver transplant patients with different donor-recipient CYP3A5 genotypes. J Clin Pharm Ther 2021. [PMID: 34708436 DOI: 10.1111/jcpt.13533] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
69 Yang N, Du Y, He J, Ge J, Wang M, Sun R, Zhu H, Ge W. Distribution evaluation of tacrolimus in the ascitic fluid of liver transplant recipients with liver cirrhosis by a sensitive ultra-performance liquid chromatography-tandem mass spectrometry method. J Sep Sci 2021. [PMID: 34694679 DOI: 10.1002/jssc.202100714] [Reference Citation Analysis]
70 Zheng P, Yu Z, Li L, Liu S, Lou Y, Hao X, Yu P, Lei M, Qi Q, Wang Z, Gao F, Zhang Y, Li Y. Predicting Blood Concentration of Tacrolimus in Patients With Autoimmune Diseases Using Machine Learning Techniques Based on Real-World Evidence. Front Pharmacol 2021;12:727245. [PMID: 34630104 DOI: 10.3389/fphar.2021.727245] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
71 Lenain R, Maanaoui M, Hamroun A, Larrue R, Van Der Hauwaert C, Gibier JB, Gnemmi V, Gomis S, Labalette M, Broly F, Hennart B, Pottier N, Hazzan M, Cauffiez C, Glowacki F. Impact of Tacrolimus Daily Dose Limitation in Renal Transplant Recipients Expressing CYP3A5: A Retrospective Study. J Pers Med 2021;11:1002. [PMID: 34683143 DOI: 10.3390/jpm11101002] [Reference Citation Analysis]
72 Li C, Lu J, Zhou S, Wei Y, Lv C, Liu T, Wu Y, Wu D, Qi J, Cai R. Influential Factors and Efficacy Analysis of Tacrolimus Concentration After Allogeneic Hematopoietic Stem Cell Transplantation in Children with β-Thalassemia Major. Pharmgenomics Pers Med 2021;14:1221-37. [PMID: 34594128 DOI: 10.2147/PGPM.S325103] [Reference Citation Analysis]
73 Henin E, Govoni M, Cella M, Laveille C, Piotti G. Therapeutic Drug Monitoring Strategies for Envarsus in De Novo Kidney Transplant Patients Using Population Modelling and Simulations. Adv Ther 2021;38:5317-32. [PMID: 34515977 DOI: 10.1007/s12325-021-01905-5] [Reference Citation Analysis]
74 Kim JM, Park P, Hong G, Joo DJ, Kim KW, Ryu JH, Han YS, Cho JY, Song G, Kim B, Kim D, Kim SH, Choi ST, You YK, Suh K, Na Y, Kang KJ, Joh J. Efficacy and safety of a switch from twice-daily tacrolimus to once-daily generic tacrolimus in stable liver transplant patients. Korean J Transplant 2021;35:168-176. [DOI: 10.4285/kjt.21.0012] [Reference Citation Analysis]
75 Bodnar-Broniarczyk M, Durlik M, Bączkowska T, Czerwińska K, Marszałek R, Pawiński T. Kidney and Liver Tissue Tacrolimus Concentrations in Adult Transplant Recipients-The Influence of the Whole Blood and Tissue Concentrations on Efficiency of Treatment during Immunosuppressive Therapy. Pharmaceutics 2021;13:1576. [PMID: 34683869 DOI: 10.3390/pharmaceutics13101576] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
76 Kirubakaran R, Hennig S, Maslen B, Day RO, Carland JE, Stocker SL. Evaluation of published population pharmacokinetic models to inform tacrolimus dosing in adult heart transplant recipients. Br J Clin Pharmacol 2021. [PMID: 34558092 DOI: 10.1111/bcp.15091] [Reference Citation Analysis]
77 Andrews LM, de Winter BCM, Cornelissen EAM, de Jong H, Hesselink DA, Schreuder MF, Brüggemann RJM, van Gelder T, Cransberg K. A Population Pharmacokinetic Model Does Not Predict the Optimal Starting Dose of Tacrolimus in Pediatric Renal Transplant Recipients in a Prospective Study: Lessons Learned and Model Improvement. Clin Pharmacokinet 2020;59:591-603. [PMID: 31654367 DOI: 10.1007/s40262-019-00831-8] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 7.0] [Reference Citation Analysis]
78 Chen L, Yang Y, Wang X, Wang C, Lin W, Jiao Z, Wang Z. Wuzhi Capsule Dosage Affects Tacrolimus Elimination in Adult Kidney Transplant Recipients, as Determined by a Population Pharmacokinetics Analysis. Pharmgenomics Pers Med 2021;14:1093-106. [PMID: 34511980 DOI: 10.2147/PGPM.S321997] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
79 Lantigua D, Trimper J, Unal B, Camci-Unal G. A new paper-based biosensor for therapeutic drug monitoring. Lab Chip 2021;21:3289-97. [PMID: 34612459 DOI: 10.1039/d1lc00473e] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
80 Bietenbeck A, Streichert T. Preparing Laboratories for Interconnected Health Care. Diagnostics (Basel) 2021;11:1487. [PMID: 34441421 DOI: 10.3390/diagnostics11081487] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
81 Aouad H, Faucher Q, Sauvage F, Pinault E, Barrot C, Arnion H, Marquet P, Essig M. Multi-omics investigation of tacrolimus nephrotoxicity.. [DOI: 10.1101/2021.07.29.454229] [Reference Citation Analysis]
82 van Gelder T, Vinks AA. Machine Learning as a Novel Method to Support Therapeutic Drug Management and Precision Dosing. Clin Pharmacol Ther 2021;110:273-6. [PMID: 34311506 DOI: 10.1002/cpt.2326] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
83 Kim EJ, Kim SJ, Huh KH, Kim BS, Kim MS, Kim SI, Kim YS, Lee J. Clinical significance of tacrolimus intra-patient variability on kidney transplant outcomes according to pre-transplant immunological risk. Sci Rep 2021;11:12114. [PMID: 34108576 DOI: 10.1038/s41598-021-91630-4] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
84 Chen Z, Cheng X, Zhang L, Tang L, Fang Y, Chen H, Zhang L, Shen A. The impact of IL-10 and CYP3A5 gene polymorphisms on dose-adjusted trough blood tacrolimus concentrations in early post-renal transplant recipients. Pharmacol Rep 2021. [PMID: 34089513 DOI: 10.1007/s43440-021-00288-2] [Reference Citation Analysis]
85 Sikma MA, Hunault CC, Huitema ADR, De Lange DW, Van Maarseveen EM. Clinical Pharmacokinetics and Impact of Hematocrit on Monitoring and Dosing of Tacrolimus Early After Heart and Lung Transplantation. Clin Pharmacokinet 2020;59:403-8. [PMID: 31820394 DOI: 10.1007/s40262-019-00846-1] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 10.0] [Reference Citation Analysis]
86 Aral AM, Zamora R, Barclay D, Yin J, El-Dehaibi F, Erbas VE, Dong L, Zhang Z, Sahin H, Gorantla VS, Vodovotz Y. The Effects of Tacrolimus on Tissue-Specific, Protein-Level Inflammatory Networks in Vascularized Composite Allotransplantation. Front Immunol 2021;12:591154. [PMID: 34017323 DOI: 10.3389/fimmu.2021.591154] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
87 Faravardeh A, Akkina S, Villicana R, Guerra G, Moten MA, Meier-Kriesche U, Stevens DR, Patel SJ, Bunnapradist S. Efficacy and Safety of Once-Daily LCP-Tacrolimus Versus Twice-Daily Immediate-Release Tacrolimus in Adult Hispanic Stable Kidney Transplant Recipients: Sub-Group Analysis from a Phase 3 Trial. Ann Transplant 2021;26:e929535. [PMID: 33859155 DOI: 10.12659/AOT.929535] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
88 Yoshikawa N, Takeshima H, Sekine M, Akizuki K, Hidaka T, Shimoda K, Ikeda R. Relationship between CYP3A5 Polymorphism and Tacrolimus Blood Concentration Changes in Allogeneic Hematopoietic Stem Cell Transplant Recipients during Continuous Infusion. Pharmaceuticals (Basel) 2021;14:353. [PMID: 33920149 DOI: 10.3390/ph14040353] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
89 Monchaud C, Bonneau A, Lemaître F. Le suivi des patients greffés. Actualités Pharmaceutiques 2021;60:26-30. [DOI: 10.1016/j.actpha.2021.02.007] [Reference Citation Analysis]
90 Lee S, Kim JM, Kim S, Rhu J, Choi G, Joh J. Early use of everolimus improved renal function after adult deceased donor liver transplantation. Korean Journal of Transplantation 2021;35:8-14. [DOI: 10.4285/kjt.20.0043] [Reference Citation Analysis]
91 Braithwaite HE, Darley DR, Brett J, Day RO, Carland JE. Identifying the association between tacrolimus exposure and toxicity in heart and lung transplant recipients: A systematic review. Transplant Rev (Orlando) 2021;35:100610. [PMID: 33756310 DOI: 10.1016/j.trre.2021.100610] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
92 Du WW, Wang XX, Zhang D, Chen WQ, Zhang XL, Li PM. Retrospective analysis on incidence and risk factors of early onset acute kidney injury after lung transplantation and its association with mortality. Ren Fail 2021;43:535-42. [PMID: 33736580 DOI: 10.1080/0886022X.2021.1883652] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
93 Fontova P, Colom H, Rigo-Bonnin R, van Merendonk LN, Vidal-Alabró A, Montero N, Melilli E, Meneghini M, Manonelles A, Cruzado JM, Torras J, Grinyó JM, Bestard O, Lloberas N. Influence of the Circadian Timing System on Tacrolimus Pharmacokinetics and Pharmacodynamics After Kidney Transplantation. Front Pharmacol 2021;12:636048. [PMID: 33815118 DOI: 10.3389/fphar.2021.636048] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
94 Pasternak AL, Marshall VD, Gersch CL, Rae JM, Englesbe M, Park JM. Evaluating the Impact of CYP3A5 Genotype on Post-Transplant Healthcare Resource Utilization in Pediatric Renal and Heart Transplant Recipients Receiving Tacrolimus. Pharmgenomics Pers Med 2021;14:319-26. [PMID: 33746516 DOI: 10.2147/PGPM.S285444] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
95 Alghanem SS, Soliman MM, Alibrahim AA, Gheith O, Kenawy AS, Awad A. Monitoring Tacrolimus Trough Concentrations During the First Year After Kidney Transplantation: A National Retrospective Cohort Study. Front Pharmacol 2020;11:566638. [PMID: 33658922 DOI: 10.3389/fphar.2020.566638] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
96 Francke MI, Andrews LM, Le HL, van de Wetering J, Clahsen-van Groningen MC, van Gelder T, van Schaik RHN, van der Holt B, de Winter BCM, Hesselink DA. Avoiding Tacrolimus Underexposure and Overexposure with a Dosing Algorithm for Renal Transplant Recipients: A Single Arm Prospective Intervention Trial. Clin Pharmacol Ther 2021;110:169-78. [PMID: 33452682 DOI: 10.1002/cpt.2163] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 8.0] [Reference Citation Analysis]
97 Kindem IA, Bjerre A, Åsberg A, Midtvedt K, Bergan S, Vethe NT. Tacrolimus Measured in Capillary Volumetric Microsamples in Pediatric Patients-A Cross-Validation Study. Ther Drug Monit 2021;43:371-5. [PMID: 33596033 DOI: 10.1097/FTD.0000000000000873] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
98 Taber DJ, Hirsch J, Keys A, Su Z, McGillicuddy JW. Etiologies and Outcomes Associated With Tacrolimus Levels Out of a Typical Range That Lead to High Variability in Kidney Transplant Recipients. Ther Drug Monit 2021;43:401-7. [PMID: 33560095 DOI: 10.1097/FTD.0000000000000863] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
99 Grabarek BO, Kasela T, Adwent I, Zawidlak-Węgrzyńska B, Brus R. Evaluation of the Influence of Adalimumab on the Expression Profile of Leptin-Related Genes and Proteins in Keratinocytes Treated with Lipopolysaccharide A. Int J Mol Sci 2021;22:1595. [PMID: 33562571 DOI: 10.3390/ijms22041595] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
100 van Eerden RAG, Oomen-de Hoop E, Noordam A, Mathijssen RHJ, Koolen SLW. Feasibility of Extrapolating Randomly Taken Plasma Samples to Trough Levels for Therapeutic Drug Monitoring Purposes of Small Molecule Kinase Inhibitors. Pharmaceuticals (Basel) 2021;14:119. [PMID: 33557114 DOI: 10.3390/ph14020119] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
101 Zhu J, Campagne O, Torrice CD, Flynn G, Miller JA, Patel T, Suzuki O, Ptachcinski JR, Armistead PM, Wiltshire T, Mager DE, Weiner DL, Crona DJ. Evaluation of the performance of a prior tacrolimus population pharmacokinetic kidney transplant model among adult allogeneic hematopoietic stem cell transplant patients. Clin Transl Sci 2021;14:908-18. [PMID: 33502111 DOI: 10.1111/cts.12956] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
102 Phan M, Chavan R, Beuttler R, Benipayo N, Magedman G, Buchbinder D, Tomaszewski D, Yang S. Evaluating risk factors for acute graft versus host disease in pediatric hematopoietic stem cell transplant patients receiving tacrolimus. Clin Transl Sci 2021;14:1303-13. [PMID: 33503293 DOI: 10.1111/cts.12982] [Reference Citation Analysis]
103 Quintairos L, Colom H, Millán O, Fortuna V, Espinosa C, Guirado L, Budde K, Sommerer C, Lizana A, López-Púa Y, Brunet M. Early prognostic performance of miR155-5p monitoring for the risk of rejection: Logistic regression with a population pharmacokinetic approach in adult kidney transplant patients. PLoS One 2021;16:e0245880. [PMID: 33481955 DOI: 10.1371/journal.pone.0245880] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
104 Miyagi SJ, Lam E, Tang Girdwood S. Partnering with Clinical Pharmacologists to Improve Medication Use in Children. J Pediatr 2020;227:5-8. [PMID: 33228913 DOI: 10.1016/j.jpeds.2020.03.061] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
105 Williams ML, Weeks HL, Beck C, Choi L. Sensitivity of Estimated Tacrolimus Population Pharmacokinetic Profile to Inaccurate Assumptions about Dose Timing and Absorption: An Investigation in Real-World and Simulated Data.. [DOI: 10.1101/2021.01.15.21249900] [Reference Citation Analysis]
106 Pinon M, De Nicolò A, Pizzol A, Antonucci M, D'Avolio A, Serpe L, Dell'Olio D, Catalano S, Tandoi F, Romagnoli R, Canaparo R, Calvo PL. Early impact of donor CYP3A5 genotype and Graft-to-Recipient Weight Ratio on tacrolimus pharmacokinetics in pediatric liver transplant patients. Sci Rep 2021;11:443. [PMID: 33432012 DOI: 10.1038/s41598-020-79574-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
107 Martuszewski A, Paluszkiewicz P, Król M, Banasik M, Kepinska M. Donor-Derived Cell-Free DNA in Kidney Transplantation as a Potential Rejection Biomarker: A Systematic Literature Review. J Clin Med 2021;10:E193. [PMID: 33430458 DOI: 10.3390/jcm10020193] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 9.0] [Reference Citation Analysis]
108 Everton JBF, Patrício FJB, Faria MS, Ferreira TCA, Romao EA, Silva GEB, Magalhães M. CYP3A5 and PPARA genetic variants are associated with low trough concentration to dose ratio of tacrolimus in kidney transplant recipients. Eur J Clin Pharmacol 2021;77:879-86. [PMID: 33398393 DOI: 10.1007/s00228-020-03076-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
109 Wu Y, Fang F, Wang Z, Wen P, Fan J. The influence of recipient SLCO1B1 rs2291075 polymorphism on tacrolimus dose-corrected trough concentration in the early period after liver transplantation. Eur J Clin Pharmacol 2021;77:859-67. [PMID: 33386894 DOI: 10.1007/s00228-020-03058-w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
110 Núñez-torres R, González-neira A. Pharmacogenetics and personalized medicine. Clinical DNA Variant Interpretation 2021. [DOI: 10.1016/b978-0-12-820519-8.00010-7] [Reference Citation Analysis]
111 Kidd JM, Asempa TE, Abdelraouf K. Therapeutic drug monitoring. Remington 2021. [DOI: 10.1016/b978-0-12-820007-0.00013-1] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
112 张 若. Advances in the Mechanism of Cytochrome P450 on Organ Transplantation. ACM 2021;11:2757-2761. [DOI: 10.12677/acm.2021.116399] [Reference Citation Analysis]
113 Radzevičienė A, Marquet P, Maslauskienė R, Vaičiūnienė R, Kaduševičius E, Stankevičius E. Analyses of AUC(0–12) and C0 Compliances within Therapeutic Ranges in Kidney Recipients Receiving Cyclosporine or Tacrolimus. JCM 2020;9:3903. [DOI: 10.3390/jcm9123903] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
114 Francke MI, Hesselink DA, Li Y, Koch BCP, de Wit LEA, van Schaik RHN, Yang L, Baan CC, van Gelder T, de Winter BCM. Monitoring the tacrolimus concentration in peripheral blood mononuclear cells of kidney transplant recipients. Br J Clin Pharmacol 2021;87:1918-29. [PMID: 33025649 DOI: 10.1111/bcp.14585] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
115 Undre N, Hussain I, Meijer J, Stanta J, Swan G, Dawson I. Quantitation of Tacrolimus in Human Whole Blood Samples Using the MITRA Microsampling Device. Ther Drug Monit 2021;43:364-70. [PMID: 33149056 DOI: 10.1097/FTD.0000000000000833] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
116 Bayne J, Francke M, Ma E, Rubin GA, Avula UMR, Baksh H, Givens R, Wan EY. Increased Incidence of Chronic Kidney Injury in African Americans Following Cardiac Transplantation. J Racial Ethn Health Disparities 2020. [PMID: 33113077 DOI: 10.1007/s40615-020-00906-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
117 Gelder TV, Etsouli O, Moes DJ, Swen JJ. Comparison of the Impact of Pharmacogenetic Variability on the PK of Slow Release and Immediate Release Tacrolimus Formulations. Genes (Basel) 2020;11:E1205. [PMID: 33076474 DOI: 10.3390/genes11101205] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
118 Wang R, Wang W, Ma K, Duan X, Wang F, Huang M, Zhang W, Liang T. Variation in Tacrolimus Trough Concentrations in Liver Transplant Patients Undergoing Endoscopic Retrograde Cholangiopancreatography: A Retrospective, Observational Study. Front Pharmacol 2020;11:1252. [PMID: 32973503 DOI: 10.3389/fphar.2020.01252] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
119 Sikma MA, Hunault CC, Van Maarseveen EM, Huitema ADR, Van de Graaf EA, Kirkels JH, Verhaar MC, Grutters JC, Kesecioglu J, De Lange DW. High Variability of Whole-Blood Tacrolimus Pharmacokinetics Early After Thoracic Organ Transplantation. Eur J Drug Metab Pharmacokinet 2020;45:123-34. [PMID: 31745812 DOI: 10.1007/s13318-019-00591-7] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
120 Kim JM, Ryu JH, Lee KW, Hong SK, Yang K, Choi GS, Kim YA, Lee JY, Yi NJ, Kwon CHD, Chu CW, Suh KS, Joh JW. Effect of CYP3A5 on the Once-Daily Tacrolimus Conversion in Stable Liver Transplant Patients. J Clin Med 2020;9:E2897. [PMID: 32911703 DOI: 10.3390/jcm9092897] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
121 Cai X, Song H, Jiao Z, Yang H, Zhu M, Wang C, Wei D, Shi L, Wu B, Chen J. Population pharmacokinetics and dosing regimen optimization of tacrolimus in Chinese lung transplant recipients. Eur J Pharm Sci 2020;152:105448. [PMID: 32621968 DOI: 10.1016/j.ejps.2020.105448] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 6.0] [Reference Citation Analysis]
122 Wang J, Huang L, Gao P, Hu Y, Ni Y, Zhu Z, Zhang L, Yang J, Zhang H, Fang L. Diltiazem on tacrolimus exposure and dose sparing in Chinese pediatric primary nephrotic syndrome: impact of CYP3A4, CYP3A5, ABCB1, and SLCO1B3 polymorphisms. Eur J Clin Pharmacol 2021;77:71-7. [PMID: 32803289 DOI: 10.1007/s00228-020-02977-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
123 Leino AD, Pai MP. Maintenance Immunosuppression in Solid Organ Transplantation: Integrating Novel Pharmacodynamic Biomarkers to Inform Calcineurin Inhibitor Dose Selection. Clin Pharmacokinet 2020;59:1317-34. [PMID: 32720300 DOI: 10.1007/s40262-020-00923-w] [Reference Citation Analysis]
124 Veenhof H, Schouw HM, Besouw MTP, Touw DJ, Gracchi V. Flucloxacillin decreases tacrolimus blood trough levels: a single-center retrospective cohort study. Eur J Clin Pharmacol 2020;76:1667-73. [PMID: 32712713 DOI: 10.1007/s00228-020-02968-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
125 Zwart TC, Moes DJAR, van der Boog PJM, van Erp NP, de Fijter JW, Guchelaar HJ, Keizer RJ, Ter Heine R. Model-Informed Precision Dosing of Everolimus: External Validation in Adult Renal Transplant Recipients. Clin Pharmacokinet 2021;60:191-203. [PMID: 32720301 DOI: 10.1007/s40262-020-00925-8] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
126 Lemaitre F, Monchaud C, Woillard JB, Picard N, Marquet P. [Summary of the recommendations of the International Association of Therapeutic Drug Monitoring and Clinical Toxicology (IATDMCT) on the therapeutic drug monitoring of tacrolimus]. Therapie 2020;75:681-5. [PMID: 32653093 DOI: 10.1016/j.therap.2020.06.004] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
127 Thongprayoon C, Hansrivijit P, Kovvuru K, Kanduri SR, Bathini T, Pivovarova A, Smith JR, Cheungpasitporn W. Impacts of High Intra- and Inter-Individual Variability in Tacrolimus Pharmacokinetics and Fast Tacrolimus Metabolism on Outcomes of Solid Organ Transplant Recipients. J Clin Med 2020;9:E2193. [PMID: 32664531 DOI: 10.3390/jcm9072193] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
128 Gustavsen MT, Midtvedt K, Robertsen I, Woillard JB, Debord J, Klaasen RA, Vethe NT, Bergan S, Åsberg A. Fasting Status and Circadian Variation Must be Considered When Performing AUC-based Therapeutic Drug Monitoring of Tacrolimus in Renal Transplant Recipients. Clin Transl Sci 2020;13:1327-35. [PMID: 32652886 DOI: 10.1111/cts.12833] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
129 van der Zwan M, Hesselink DA, van den Hoogen MWF, Baan CC. Costimulation Blockade in Kidney Transplant Recipients. Drugs 2020;80:33-46. [PMID: 31749062 DOI: 10.1007/s40265-019-01226-6] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 6.0] [Reference Citation Analysis]
130 Yamamoto Y, Nakase H, Matsuura M, Maruyama S, Masuda S. CYP3A5 Genotype as a Potential Pharmacodynamic Biomarker for Tacrolimus Therapy in Ulcerative Colitis in Japanese Patients. Int J Mol Sci 2020;21:E4347. [PMID: 32570960 DOI: 10.3390/ijms21124347] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
131 Quinlan C. The Future of Paediatric Nephrology—Genomics and Personalised Precision Medicine. Curr Pediatr Rep 2020;8:115-21. [DOI: 10.1007/s40124-020-00218-5] [Reference Citation Analysis]
132 Prado-Velasco M, Borobia A, Carcas-Sansuan A. Predictive engines based on pharmacokinetics modelling for tacrolimus personalized dosage in paediatric renal transplant patients. Sci Rep 2020;10:7542. [PMID: 32371893 DOI: 10.1038/s41598-020-64189-9] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
133 Zhang M, Tajima S, Shigematsu T, Fu R, Noguchi H, Kaku K, Tsuchimoto A, Okabe Y, Egashira N, Masuda S. Donor CYP3A5 Gene Polymorphism Alone Cannot Predict Tacrolimus Intrarenal Concentration in Renal Transplant Recipients. Int J Mol Sci 2020;21:E2976. [PMID: 32340188 DOI: 10.3390/ijms21082976] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
134 Bonneville E, Gautier-Veyret E, Ihl C, Hilleret MN, Baudrant M, Fonrose X, Stanke-Labesque F. Unexpected overdose blood concentration of tacrolimus: Keep in mind the role of inflammation. Br J Clin Pharmacol 2020;86:1888-91. [PMID: 32199027 DOI: 10.1111/bcp.14292] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
135 Zarrinpar A, Kim UB, Boominathan V. Phenotypic Response and Personalized Medicine in Liver Cancer and Transplantation: Approaches to Complex Systems. Adv Therap 2020;3:1900167. [DOI: 10.1002/adtp.201900167] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
136 Nakamura T, Fukuda M, Matsukane R, Suetsugu K, Harada N, Yoshizumi T, Egashira N, Mori M, Masuda S. Influence of POR*28 Polymorphisms on CYP3A5*3-Associated Variations in Tacrolimus Blood Levels at an Early Stage after Liver Transplantation. Int J Mol Sci 2020;21:E2287. [PMID: 32225074 DOI: 10.3390/ijms21072287] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
137 Tron C, Woillard JB, Houssel-Debry P, David V, Jezequel C, Rayar M, Balakirouchenane D, Blanchet B, Debord J, Petitcollin A, Roussel M, Verdier MC, Bellissant E, Lemaitre F. Pharmacogenetic-Whole blood and intracellular pharmacokinetic-Pharmacodynamic (PG-PK2-PD) relationship of tacrolimus in liver transplant recipients. PLoS One 2020;15:e0230195. [PMID: 32163483 DOI: 10.1371/journal.pone.0230195] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 8.5] [Reference Citation Analysis]
138 Veenhof H, van Boven JFM, van der Voort A, Berger SP, Bakker SJL, Touw DJ. Effects, costs and implementation of monitoring kidney transplant patients' tacrolimus levels with dried blood spot sampling: A randomized controlled hybrid implementation trial. Br J Clin Pharmacol 2020;86:1357-66. [PMID: 32077134 DOI: 10.1111/bcp.14249] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 5.0] [Reference Citation Analysis]
139 Yousef B, Idress T, Badi S. Assessment of knowledge and practice of Sudanese renal transplant recipients about tacrolimus usage: A cross-sectional study. Int J Health Allied Sci 2020;9:136. [DOI: 10.4103/ijhas.ijhas_110_19] [Reference Citation Analysis]
140 Seger C. Assessing immunosuppressive drug concentrations in clinical practice. Handbook of Analytical Separations 2020. [DOI: 10.1016/b978-0-444-64066-6.00012-5] [Reference Citation Analysis]
141 Budde K, Halleck F. Risks and benefits of everolimus. Transpl Int 2019;32:1124-6. [PMID: 31397931 DOI: 10.1111/tri.13489] [Reference Citation Analysis]
142 Grujičić M, Žigić M, Maksić M, Hajder S, Golić D, Gašić B, Rakanović D, Vasić N, Laganin N, Roljić Z, Stajčić L, Mišković M, Mićić-zrnić D, Topić G, Đajić V. Results of the kidney transplant programme at the University Clinical Centre of the Republic of Srpska from 2010 to 2018. Scripta Medica 2019;50:82-8. [DOI: 10.5937/scriptamed50-22278] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]